Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

Inclusion Criteria:

• Age: 18-75 years old; Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤ 1; Predicted survival ≥12 weeks.
• Subjects with hepatocellular carcinoma (HCC) confirmed by histopathology or cytologyor who meet the diagnostic criteria for Primary Liver Cancer 2022 or the AmericanAssociation for the Study of Hepatology (AASLD) hepatocellular carcinoma.
• Subjects who received radical excision or ablation (Radio Frequency Ablation (RFA) orMicrowave Ablation (MWA) only) within 4 to 12 weeks prior to randomization (multiplemodalities or combined or multiple treatments are not acceptable).
• No major vena portae 3 (Vp3) or vena portae 4 (Vp4) in the portal vein or any level ofvascular invasion in the hepatic vein or inferior vena cava.
• No extrahepatic metastasis.
• High risk factors for recurrence after radical resection or complete ablation.
• Complete recovery from surgical resection or ablation within 4 weeks beforerandomization.

Exclusion Criteria:

• Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCChistology.
• Evidence of residual, recurrent, or metastatic disease at randomization.
• More than one surgical treatment for hepatocellular carcinoma; Received more than 1prophylactic Transcatheter Arterial Chemoembolization (TACE) treatment after surgery;or received Hepatic Artery Infusion Chemotherapy (HAIC) therapy after surgery.
• Previous use of antiangiogenic drugs or PD-1, Programmed Cell Death-Ligand 1 (PD-L1)and other related immunotherapy drugs or systemic chemotherapy drugs.